A Comparative Study of 2 Doses of BM Autologous H-MSC+Biomaterial vs Iliac Crest AutoGraft for Bone Healing in Non-Union

  • End date
    Dec 30, 2021
  • participants needed
  • sponsor
    Universidad Autonoma de Madrid
Updated on 23 January 2021


ORTHOUNION is a multi-centre, open, comparative, randomized, clinical trial with three parallel arms that aims to compare the efficacy of three treatments to enhance bone healing in patients with long bone non-union.


Bone injuries represent an important world medical problem producing significant healthcare and societal expenditure. While most bone injuries are not severe and are capable of healing through bone regeneration by natural callus formation with standard treatments, severe bone injuries may not heal, becoming an important unmet clinical need.

Non-unions, or pseudarthrosis, may occur in 5% to 20% of long-bone fractures that fail to heal properly after more than 6 months, with morbidity, prolonged hospitalization, and increased expenses. The most commonly accepted standard augmentation to procure fracture and non-union healing consists of autologous bone grafting, obtained from the same patient in a different surgical site and transplanted to the reconstruction site. However, autologous bone grafting has some drawbacks (such as persistent pain, scar, late recovery, limited amount of bone, etc) and a limited regeneration efficacy (success rate of about 74%) and high societal cost. Culture-expanded autologous MSCs combined with biphasic calcium phosphate (BCP) biomaterial granules have been claimed as a solid regenerative medicine alternative to autologous bone grafting in non-unions, although current data are limited. In this context, the ORTHOUNION initiative focuses on the opportunity to test the hypothesis of superiority of MSC, the investigational ATMP, versus the currently accepted standard therapy, iliac crest bone autograft to biologically augment surgical treatment of long-bone non-unions.

Condition Nonunion of fracture, fracture nonunion
Treatment Cultured Mesenchymal Cells, Autologous iliac crest graft, Cultured Mesenchymal Stem Cells
Clinical Study IdentifierNCT03325504
SponsorUniversidad Autonoma de Madrid
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Age 18 years and older, both sexes
Traumatic isolated closed or open Gustilo I and II, IIIA and IIIB humerus, tibial or femur diaphyseal or metaphysodiaphyseal fracture with a status of atrophic, oligotrophic or normotrophic non-union
Able to understand, accept and sign informed consent
Medical health coverage
Able to understand and accept the study constraints

Exclusion Criteria

Hypertrophic non-unions
Segmental bone loss requiring specific therapy (bone transport, vascularized graft, large structural allograft, megaprosthesis, etc)
Unrecovered vascular or neural injury
Other fractures causing interference with weight bearing
Visceral injuries or diseases interfering with callus formation (severe cranioencephalic trauma, etc.)
Active infection of any location and aetiology
Surgical contraindication of any cause
Pregnancy, breast feeding women and women who are of childbearing age and not practicing adequate birth control
Malignant tumour (past history or concurrent disease)(except carcinoma in situ or basalioma in remission)
History of bone harvesting on iliac crest contraindicating new iliac crest bone graft harvesting or bone marrow collection
Insulin dependent diabetes
Any evidence (confirmed by PCR) of active infection with HIV, Hepatitis B or Hepatitis C infection
Any evidence of Syphilis
Known allergies to products involved in the production process of MSC
Corticoid or immunosuppressive therapy more than one week in the three months prior to study inclusion
Autoimmune inflammatory disease
Current treatment by biphosphonates not stopped three months prior to study inclusion
Impossibility to meet at the appointments for the follow up
Participation in another therapeutic trial in the previous 3 months
Second non-union in case of bilateral or multiple non-unions (only one non-union per patient will be included in the trial)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note